Icatibant Fresenius

Icatibant acetate, the active ingredient in Icatibant Fresenius, is a Bradykinin B2 receptor antagonist presented as a solution for subcutaneous use. It treats hereditary angioedema attacks in patients with a confirmed diagnosis. GNH USA supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant Fresenius is used to manage bradykinin‑mediated hereditary angioedema attacks. - Hereditary angioedema type I: provides rapid reduction of swelling and pain during acute attacks. - Hereditary angioedema type II: accelerates resolution of edema and improves patient comfort. - Hereditary angioedema with normal C1‑INH: offers symptom control when attacks are triggered by elevated bradykinin.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin flushing. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: sudden drop in blood pressure. - Angioedema unrelated to HAE: unexpected swelling in other body parts. - Urticaria: widespread hives. - Thrombocytopenia: low platelet count. - Serum sickness–like reaction: fever, rash, arthralgia.

Before using Icatibant, certain safety considerations should be observed. - Pregnancy: safety not established; avoid unless clearly needed. - Breastfeeding: unknown effects; weigh benefits against potential risks. - Renal impairment: use with caution; monitor renal function. - Concomitant ACE inhibitors: increased bradykinin may heighten adverse reactions. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence the bradykinin pathway or cardiovascular status.

Major Interactions (Avoid): - ACE inhibitors: may amplify bradykinin‑related effects, increasing risk of angioedema. - Neprilysin inhibitors (e.g., sacubitril): can raise bradykinin levels, heightening adverse events.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate swelling or pain if angioedema worsens. - Other bradykinin‑modulating agents: monitor for additive effects. - Diuretics: watch for blood pressure changes.